Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Resistance mechanisms to taxanes and PARP inhibitors in advanced prostate cancer

Current Opinion in Endocrine and Metabolic Research(2020)10.1016/j.coemr.2020.02.006Source: DataRank Database

Resistance mechanisms to taxanes and PARP inhibitors in advanced prostate cancer is a research paper published in Current Opinion in Endocrine and Metabolic Research (2020). On theSindex it has a DataRank of 0. It has been cited 10 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access10 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (3 grants)Impact (FWCI 0.77)OA: greenTopics (35)IDs (PubMed, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (2)

Allen C. Gao ORCID,Alan P. Lombard ORCID

Live enrichment

PubMed:32258820 OpenAlex:https://openalex.org/W3007533110

National Institutes of Health

Grant: 1R01CA168601-01A1

Novel roles of microRNA in androgen receptor signaling

National Institutes of Health

Grant: 5R01CA225836-04

Targeting AR variants in advanced prostate cancer

National Institutes of Health

Grant: 5R21CA179970-02

(PQD-1) NF-kB activation and enzalutamide therapy in metastatic castration resist

FWCI

0.77

Citation Percentile

0.7%

Citation Trend

2019

2021

2022

2023

2024

2025

greenLicense: Elsevier TDM

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/7111181

publisherhttps://api.elsevier.com/content/article/PII:S2451965020300119?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S2451965020300119?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.coemr.2020.02.006

Fields of Study

Prostate Cancer Treatment and ResearchProstate Cancer Diagnosis and TreatmentPARP inhibition in cancer therapy0301 basic medicine0303 health sciences03 medical and health sciences

Keywords

Prostate cancerTaxaneMedicineAndrogen receptorPARP inhibitorDrug resistanceAndrogen deprivation therapyDNA repairOncologyCancerCancer researchBioinformaticsInternal medicinePoly ADP ribose polymeraseBreast cancerBiologyDNAUrologic DiseasesAgingCabazitaxelResistanceEvaluation of treatments and therapeutic interventionsDocetaxelOlaparibClinical Research5.1 Pharmaceuticals6.1 PharmaceuticalsPatient SafetyDevelopment of treatments and therapeutic interventions

Sustainable Development Goals

SDG 3: 3. Good health